{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Inecalcitol",
  "nciThesaurus": {
    "casRegistry": "163217-09-2",
    "chebiId": "",
    "chemicalFormula": "C26H40O3",
    "definition": "An analog of calcitriol and a vitamin D3 receptor (VDR) agonist, with potential antineoplastic activity. Upon administration, inecalcitol targets and binds to VDR. This activates VDR and VDR-mediated signal transduction pathways. This modulates the VDR-mediated expression of certain genes, including the expression of anti-cancer genes, enhances cellular differentiation, induces tumor cell apoptosis and inhibits tumor cell growth. VDR plays a central role in calcium homeostasis and in the growth of certain cancer cells.",
    "fdaUniiCode": "05FZV98342",
    "identifier": "C83818",
    "preferredName": "Inecalcitol",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C39713"
    ],
    "synonyms": [
      "(7E)-19-Nor-9,10-seco-14beta-cholesta-5,7-dien-23-yne-1alpha,3beta,25-triol",
      "ICC",
      "INECALCITOL",
      "Inecalcitol",
      "TX 522"
    ]
  }
}